Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 7, 2012 - Issue 4
Submit an article Journal homepage
1,554
Views
4
CrossRef citations to date
0
Altmetric
Drug Profile

Optimizing treatment strategies with insulin glargine in Type 2 diabetes

David R Owens Centre for Endocrine & Diabetes Sciences, Cardiff University, University Hospital Llandough, Penarth, UK. [email protected]
Pages 377-393 | Published online: 10 Jan 2014

References

  • Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can. Med. Assoc. J. 12(3), 141–146 (1922).
  • Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 94(3), 311–321 (2011).
  • Lawrence RD, Madders K. Employment of diabetics. Br. Med. J. 2(4064), 1076–1077 (1938).
  • Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49(12), 2142–2148 (2000).
  • Zeuzem S, Stahl E, Jungmann E, Zoltobrocki M, Schöffling K, Caspary WF. In vitro activity of biosynthetic human diarginylinsulin. Diabetologia 33(2), 65–71 (1990).
  • Monti LD, Poma R, Caumo A et al. Intravenous infusion of diarginylinsulin, an insulin analogue: effects on glucose turnover and lipid levels in insulin-treated type II diabetic patients. Metab. Clin. Exp. 41(5), 540–544 (1992).
  • Jørgensen S, Vaag A, Langkjaer L, Hougaard P, Markussen J. NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue. BMJ 299(6696), 415–419 (1989).
  • Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 23(6), 813–819 (2000).
  • Kuerzel G, Sandow J, Seipke G, Lang A, Maas Skrzipczyk HJ. Kinetic and metabolite profile of insulin glargine. Diabetologia 44(Suppl. 1), A798 (2001).
  • Kuerzel GU, Shukla U, Scholtz HE et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr. Med. Res. Opin. 19(1), 34–40 (2003).
  • Lucidi P, Portcellati F, Rossetti P et al. Metabolism of insulin glargine after sc injection of therapeutic dose in Type 2 diabetes mellitus. Presented at: 71st Scientific Sessions of the American Diabetes Association. San Diego, CA, USA, 24–28 June 2011 (Poster 071-OR).
  • Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time–action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23(5), 644–649 (2000).
  • Hamilton-Wessler M, Ader M, Dea M et al. Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. Diabetologia 42(10), 1254–1263 (1999).
  • Kurtzhals P, Havelund S, Jonassen I, Markussen J. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J. Pharm. Sci. 86(12), 1365–1368 (1997).
  • Vigneri R, Squatrito S, Sciacca L. Insulin and its analogs: actions via insulin and IGF receptors. Acta Diabetol. 47(4), 271–278 (2010).
  • Brunner GA, Sendhofer G, Wutte A et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp. Clin. Endocrinol. Diabetes 108(2), 100–105 (2000).
  • Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time–action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet. Med. 16(4), 332–338 (1999).
  • Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with Type 2 diabetes. Diabetologia 51(3), 408–416 (2008).
  • Holman RR, Farmer AJ, Davies MJ et al.; 4-T Study Group. Three-year efficacy of complex insulin regimens in Type 2 diabetes. N. Engl. J. Med. 361(18), 1736–1747 (2009).
  • Porcellati F, Rossetti P, Busciantella NR et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in Type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 30(10), 2447–2452 (2007).
  • Hollander P, Cooper J, Bregnhøj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with Type 2 diabetes. Clin. Ther. 30(11), 1976–1987 (2008).
  • Nathan DM, Buse JB, Davidson MB et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1), 193–203 (2009).
  • Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in Type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association of Diabetes (EASD). Diabetologia 55, 1577–1596 (2012).
  • Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of Type 2 diabetic patients. Diabetes Care 26(11), 3080–3086 (2003).
  • Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in Type 2 diabetes: the LANMET study. Diabetologia 49(3), 442–451 (2006).
  • Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in Type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24(4), 631–636 (2001).
  • Yki-Järvinen H, Dressler A, Ziemen M; HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in Type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 23(8), 1130–1136 (2000).
  • Pan CY, Sinnassamy P, Chung KD, Kim KW; LEAD Study Investigators Group. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabetes Res. Clin. Pract. 76(1), 111–118 (2007).
  • Eliaschewitz FG, Calvo C, Valbuena H et al.; HOE 901/4013 LA Study Group. Therapy in Type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch. Med. Res. 37(4), 495–501 (2006).
  • Fritsche A, Schweitzer MA, Häring HU; 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with Type 2 diabetes. A randomized, controlled trial. Ann. Intern. Med. 138(12), 952–959 (2003).
  • Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with Type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am. J. Med. Sci. 328(5), 274–280 (2004).
  • Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with Type 2 diabetes. Horm. Metab. Res. 35(3), 189–196 (2003).
  • HOE 901/2004 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabet. Med. 20(7), 545–551 (2003).
  • Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet. Med. 25(8), 924–932 (2008).
  • Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in Type 1 and Type 2 diabetes mellitus. Clin. Ther. 29(8), 1607–1619 (2007).
  • Home PD, Fritsche A, Schinzel S, Massi-Benedetti M. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with Type 2 diabetes using NPH insulin or insulin glargine. Diabetes. Obes. Metab. 12(9), 772–779 (2010).
  • Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet. Med. 25(3), 245–254 (2008).
  • Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 57(12), 3169–3176 (2008).
  • Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet. Med. 23(7), 736–742 (2006).
  • Kennedy L, Herman WH, Strange P, Harris A; GOAL AIC Team. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with Type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) Trial. Diabetes Care 29(1), 1–8 (2006).
  • Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled Type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28(6), 1282–1288 (2005).
  • Tanenberg R, Zisman A, Stewart J. Glycemia optimization treatment (GOT): glycemic control and rate of severe hypoglycemia for five different dosing algorithms of insulin glargine (GLAR) in patients with Type 2 diabetes mellitus (T2DM). Diabetes 55(Suppl. 1), abstract 567-P (2006).
  • Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with Type 2 diabetes. Diabetes Care 29(6), 1269–1274 (2006).
  • Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir versus insulin glargine for Type 2 diabetes mellitus. Cochrane Database Syst. Rev. 7, CD006383 (2011).
  • Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with Type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371(9618), 1073–1084 (2008).
  • Holman RR, Thorne KI, Farmer AJ et al.; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in Type 2 diabetes. N. Engl. J. Med. 357(17), 1716–1730 (2007).
  • Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for Type 2 diabetes. Diabetes Care 28(2), 254–259 (2005).
  • Raskin P, Allen E, Hollander P et al.; INITIATE Study Group. Initiating insulin therapy in Type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28(2), 260–265 (2005).
  • Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in Type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 31(1), 20–25 (2008).
  • Fritsche A, Larbig M, Owens D, Häring HU; GINGER study group. Comparison between a basal-bolus and a premixed insulin regimen in individuals with Type 2 diabetes–results of the GINGER study. Diabetes. Obes. Metab. 12(2), 115–123 (2010).
  • Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA; Orals Plus Apidra and LANTUS (OPAL) study group. Introducing a simplified approach to insulin therapy in Type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes. Obes. Metab. 10(12), 1178–1185 (2008).
  • Owens D, Sert-Langeron C, Riddle MC. Adding a single dose of insulin glulisine to basal insulin glargine plus oral antihyperglycemic drug therapy improves glycemic control in Type 2 diabetes: a 6-month proof-of-concept study [abstract]. Diabetes 58(Suppl. 1), A122 (2009).
  • Raccah D. Stepwise intensification of prandial insulin versus basal−bolus insulin therapy in patients with Type 2 diabetes mellitus. Presented at: 46th Annual Meeting of the European Association for the Study of Diabetes. Stockholm, Sweden, 20–24 September 2010 (Abstract 958).
  • Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P. A stepwise approach to insulin therapy in patients with Type 2 diabetes mellitus and basal insulin treatment failure. Endocr. Pract. 17(3), 395–403 (2011).
  • Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in Type 2 diabetes. Diabetes Care 28(4), 950–955 (2005).
  • Tsai ST, Pathan F, Ji L et al. First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia. J. Diabetes 3(3), 208–216 (2011).
  • McNeely MJ, Boyko EJ. Type 2 diabetes prevalence in Asian Americans: results of a national health survey. Diabetes Care 27(1), 66–69 (2004).
  • Shahar D, Fraser D, Shai I, Vardi H. Development of a food frequency questionnaire (FFQ) for an elderly population based on a population survey. J. Nutr. 133(11), 3625–3629 (2003).
  • Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch. Intern. Med. 157(15), 1681–1686 (1997).
  • Greco D, Angileri G. Drug-induced severe hypoglycaemia in Type 2 diabetic patients aged 80 years or older. Diabetes Nutr. Metab. 17(1), 23–26 (2004).
  • Lee P, Chang A, Blaum C, Vlajnic A, Gao L, Halter J. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with Type 2 diabetes mellitus: results from a pooled analysis. J. Am. Geriatr. Soc. 60(1), 51–59 (2012).
  • Kawamori R, Kadawaki T, Iwasaki M. Efficacy and safety of insulin glargine in concurrent use with oral hypoglycemic agents for the treatment of Type 2 diabetic patients. J. Clin. Therap. Med. 19(5), 445–464 (2003).
  • Kanazawa Y, Igarashi Y, Komiya K et al. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between Type 1 and Type 2 diabetes (JUN-LAN Study 1.2). Endocr. J. 54(6), 975–983 (2007).
  • Fonseca V, Gill J, Zhou R, Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes. Metab. 13(9), 814–822 (2011).
  • Arnolds S, Dellweg S, Clair J et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 33(7), 1509–1515 (2010).
  • Buse JB, Bergenstal RM, Glass LC et al. Use of twice-daily exenatide in basal insulin-treated patients with Type 2 diabetes: a randomized, controlled trial. Ann. Intern. Med. 154(2), 103–112 (2011).
  • Seino Y, Min K, Niemoller E, Takami A. 0278-OR lixisenatide significantly improves glycemic control in Asian patients with T2DM insufficiently controlled on basal insulin ± SU. Diabetes Obes. Metab. (doi: 10.1111/j.1463-1326.2012.01618.x) (2011) (Epub ahead of print).
  • Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: a consensus report. Diabetes Care 33(7), 1674–1685 (2010).
  • Johnson JA, Pollak M. Insulin, glucose and the increased risk of cancer in patients with Type 2 diabetes. Diabetologia 53(10), 2086–2088 (2010).
  • Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8(12), 915–928 (2008).
  • Ciaraldi TP, Sasaoka T. Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities. Horm. Metab. Res. 43(1), 1–10 (2011).
  • Le Roith D. The insulin-like growth factor system. Exp. Diabesity Res. 4(4), 205–212 (2003).
  • LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat. Clin. Pract. Endocrinol. Metab. 3(3), 302–310 (2007).
  • Fawcett J, Tsui BT, Kruer MC, Duckworth WC. Reduced action of insulin glargine on protein and lipid metabolism: possible relationship to cellular hormone metabolism. Metab. Clin. Exp. 53(8), 1037–1044 (2004).
  • Sommerfeld MR, Müller G, Tschank G et al. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS ONE 5(3), e9540 (2010).
  • Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52(9), 1755–1765 (2009).
  • Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in Type 2 diabetes. Diabetologia 52(9), 1766–1777 (2009).
  • Hemkens LG, Grouven U, Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52(9), 1732–1744 (2009).
  • Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies–a population-based follow-up study in Sweden. Diabetologia 52(9), 1745–1754 (2009).
  • Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 374(9689), 511–513 (2009).
  • Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 52(9), 1699–1708 (2009).
  • Suissa S, Azoulay L, Dell’Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 54(9), 2254–2262 (2011).
  • Ljung R, Talbäck M, Haglund B, Jonasson JM, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies – a three-year population-based observation. Acta Oncol. 50(5), 685–693 (2011).
  • Rosenstock J, Fonseca V, McGill JB et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with Type 2 diabetes: a long-term, randomised, open-label study. Diabetologia 52(9), 1778–1788 (2009).
  • Rosenstock J, Fonseca V, McGill JB et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with Type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 52(9), 1971–1973 (2009).
  • The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. doi: 10.1056/nejmoa1203858 (2012) (Epub ahead of print).
  • Boyle P, Koechlin A, Boniol M, Robertson C, Bolli GB, Rosenstock J. Updated meta-analysis of cancer risk among users of insulin glargine. Diabetes 61(Suppl. 1), A345 (1332-P) (2012).
  • Grimaldi-Bensouda L, Marty M, Pollak M et al. The international study of insulin and cancer. Lancet 376, 769–770 (2010).
  • Garg SK, Hirsch IB, Skyler JS. Insulin glargine and cancer – an unsubstantiated allegation. Diabetes Technol. Ther. 11(8), 473–476 (2009).
  • Blin P, Lassalle R, Dureau-Pournin C et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 55(3), 644–653 (2012).
  • Lind M, Fahlen M, Eliasson B, Oden A. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim. Care Diabetes 6(1), 53–59 (2012).
  • van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 55(3), 654–665 (2012).
  • Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with Type 2 diabetes. Diabetes Metab. Res. Rev. 25(6), 542–548 (2009).
  • Swinnen SG, Dain MP, Aronson R et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with Type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 33(6), 1176–1178 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.